Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7012841 | 0.78 | CRHR1 (0.41) | CRHR1 | |
| SCHEMBL14275131 | 0.77 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL7015721 | 0.73 | CRHR1 (0.37) | CRHR1 | |
| SCHEMBL6053133 | 0.63 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL5571780 | 0.62 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7891179 | 0.62 | ALDH1A1 (0.39) | CRHR1 | |
| SCHEMBL23608284 | 0.60 | LMNA (0.32) | — | |
| SCHEMBL7216722 | 0.59 | CRHR1 (0.54) | CRHR1 | |
| SCHEMBL24316526 | 0.58 | — | — | |
| SCHEMBL12384206 | 0.57 | CRHR1 (0.41) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697362-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB PHARMCO INC (PR) | 2008-03-05 | — | — | EP | disclosed |
| EP-1697362-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB PHARMCO INC (PR) | 2008-03-05 | — | — | EP | disclosed |
| US-20070293508-A1 | Crf Receptor Antagonists and Methods Relating Thereto | SB PHARMCO PUERTO RICO INC AND NEUROCRINE BIOSCIENCES, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293508-A1 | Crf Receptor Antagonists and Methods Relating Thereto | SB PHARMCO PUERTO RICO INC AND NEUROCRINE BIOSCIENCES, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293508-A1 | Crf Receptor Antagonists and Methods Relating Thereto | SB PHARMCO PUERTO RICO INC AND NEUROCRINE BIOSCIENCES, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1697362-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB Pharmco Puerto Rico Inc. (PR) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063749-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB PHARMCO PUERTO RICO INC (GB) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293508-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, SCTR | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.